205 related articles for article (PubMed ID: 25142337)
1. Structural basis of valmerins as dual inhibitors of GSK3β/CDK5.
Li X; Wang X; Tian Z; Zhao H; Liang D; Li W; Qiu Y; Lu S
J Mol Model; 2014 Sep; 20(9):2407. PubMed ID: 25142337
[TBL] [Abstract][Full Text] [Related]
2. Advances in tetrahydropyrido[1,2-a]isoindolone (valmerins) series: Potent glycogen synthase kinase 3 and cyclin dependent kinase 5 inhibitors.
Boulahjar R; Ouach A; Bourg S; Bonnet P; Lozach O; Meijer L; Guguen-Guillouzo C; Le Guevel R; Lazar S; Akssira M; Troin Y; Guillaumet G; Routier S
Eur J Med Chem; 2015 Aug; 101():274-87. PubMed ID: 26142492
[TBL] [Abstract][Full Text] [Related]
3. Interplay between cyclin-dependent kinase 5 and glycogen synthase kinase 3 beta mediated by neuregulin signaling leads to differential effects on tau phosphorylation and amyloid precursor protein processing.
Wen Y; Planel E; Herman M; Figueroa HY; Wang L; Liu L; Lau LF; Yu WH; Duff KE
J Neurosci; 2008 Mar; 28(10):2624-32. PubMed ID: 18322105
[TBL] [Abstract][Full Text] [Related]
4. Structural features underlying selective inhibition of GSK3β by dibromocantharelline: implications for rational drug design.
Zhang N; Zhong R; Yan H; Jiang Y
Chem Biol Drug Des; 2011 Mar; 77(3):199-205. PubMed ID: 21244636
[TBL] [Abstract][Full Text] [Related]
5. Binding mechanism of CDK5 with roscovitine derivatives based on molecular dynamics simulations and MM/PBSA methods.
Dong K; Wang X; Yang X; Zhu X
J Mol Graph Model; 2016 Jul; 68():57-67. PubMed ID: 27371933
[TBL] [Abstract][Full Text] [Related]
6. Hippocampal glycogen synthase kinase 3β is critical for the antidepressant effect of cyclin-dependent kinase 5 inhibitor in rats.
Li G; Liu T; Kong X; Wang L; Jin X
J Mol Neurosci; 2014 Sep; 54(1):92-9. PubMed ID: 24563226
[TBL] [Abstract][Full Text] [Related]
7. Novel optimization of valmerins (tetrahydropyrido[1,2-a]isoindolones) as potent dual CDK5/GSK3 inhibitors.
Ouach A; Boulahjar R; Vala C; Bourg S; Bonnet P; Guguen-Guillouzo C; Ravache M; Le Guevel R; Lozach O; Lazar S; Troin Y; Meijer L; Ruchaud S; Akssira M; Guillaumet G; Routier S
Eur J Med Chem; 2016 Jun; 115():311-25. PubMed ID: 27019296
[TBL] [Abstract][Full Text] [Related]
8. Theoretical Studies on the Selectivity Mechanisms of Glycogen Synthase Kinase 3β (GSK3β) with Pyrazine ATP-competitive Inhibitors by 3DQSAR, Molecular Docking, Molecular Dynamics Simulation and Free Energy Calculations.
Zhu J; Wu Y; Xu L; Jin J
Curr Comput Aided Drug Des; 2020; 16(1):17-30. PubMed ID: 31284868
[TBL] [Abstract][Full Text] [Related]
9. An evaluation of indirubin analogues as phosphorylase kinase inhibitors.
Begum J; Skamnaki VT; Moffatt C; Bischler N; Sarrou J; Skaltsounis AL; Leonidas DD; Oikonomakos NG; Hayes JM
J Mol Graph Model; 2015 Sep; 61():231-42. PubMed ID: 26364215
[TBL] [Abstract][Full Text] [Related]
10. Virtual screening, pharmacokinetics, molecular dynamics and binding free energy analysis for small natural molecules against cyclin-dependent kinase 5 for Alzheimer's disease.
Shukla R; Singh TR
J Biomol Struct Dyn; 2020 Jan; 38(1):248-262. PubMed ID: 30688165
[TBL] [Abstract][Full Text] [Related]
11. Studying the mechanism that enables paullones to selectively inhibit glycogen synthase kinase 3 rather than cyclin-dependent kinase 5 by molecular dynamics simulations and free-energy calculations.
Chen Q; Cui W; Cheng Y; Zhang F; Ji M
J Mol Model; 2011 Apr; 17(4):795-803. PubMed ID: 20559856
[TBL] [Abstract][Full Text] [Related]
12. A rational approach to selective pharmacophore designing: an innovative strategy for specific recognition of Gsk3β.
Pradeep H; Rajanikant GK
Mol Divers; 2012 Aug; 16(3):553-62. PubMed ID: 22918724
[TBL] [Abstract][Full Text] [Related]
13. Identification of dual kinase inhibitors of CK2 and GSK3β: combined qualitative and quantitative pharmacophore modeling approach.
Pardhi T; Vasu K
J Biomol Struct Dyn; 2018 Jan; 36(1):177-194. PubMed ID: 27960601
[TBL] [Abstract][Full Text] [Related]
14. CDK5 activator protein p25 preferentially binds and activates GSK3β.
Chow HM; Guo D; Zhou JC; Zhang GY; Li HF; Herrup K; Zhang J
Proc Natl Acad Sci U S A; 2014 Nov; 111(45):E4887-95. PubMed ID: 25331900
[TBL] [Abstract][Full Text] [Related]
15. Cyclin-dependent protein kinase 5 primes microtubule-associated protein tau site-specifically for glycogen synthase kinase 3beta.
Li T; Hawkes C; Qureshi HY; Kar S; Paudel HK
Biochemistry; 2006 Mar; 45(10):3134-45. PubMed ID: 16519508
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and biological evaluation of 1-phenylpyrazolo[3,4-e]pyrrolo[3,4-g]indolizine-4,6(1H,5H)-diones as new glycogen synthase kinase-3β inhibitors.
La Pietra V; La Regina G; Coluccia A; Famiglini V; Pelliccia S; Plotkin B; Eldar-Finkelman H; Brancale A; Ballatore C; Crowe A; Brunden KR; Marinelli L; Novellino E; Silvestri R
J Med Chem; 2013 Dec; 56(24):10066-78. PubMed ID: 24295046
[TBL] [Abstract][Full Text] [Related]
17. Identification and in vitro evaluation of new leads as selective and competitive glycogen synthase kinase-3β inhibitors through ligand and structure based drug design.
Darshit BS; Balaji B; Rani P; Ramanathan M
J Mol Graph Model; 2014 Sep; 53():31-47. PubMed ID: 25064440
[TBL] [Abstract][Full Text] [Related]
18. Docking and quantitative structure-activity relationship of oxadiazole derivates as inhibitors of GSK3β.
Quesada-Romero L; Caballero J
Mol Divers; 2014 Feb; 18(1):149-59. PubMed ID: 24081608
[TBL] [Abstract][Full Text] [Related]
19. Kinase inhibitor scaffolds against neurodegenerative diseases from a Southern Australian ascidian, Didemnum sp.
Plisson F; Conte M; Khalil Z; Huang XC; Piggott AM; Capon RJ
ChemMedChem; 2012 Jun; 7(6):983-90. PubMed ID: 22532438
[TBL] [Abstract][Full Text] [Related]
20. Cyclin-dependent kinases 5 template: useful for virtual screening.
Pitchuanchom S; Boonyarat C; Forli S; Olson AJ; Yenjai C
Comput Biol Med; 2012 Jan; 42(1):106-11. PubMed ID: 22079569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
